Ropivacaine clearance is reduced in chronic end-stage liver disease

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1573, 2007-01, pp. : 19-19

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New Management Options for End-Stage Chronic Liver Disease and Acute Liver Failure: Potential for Pediatric Patients

By Debray Dominique

Pediatric Drugs, Vol. 8, Iss. 1, 2006-01 ,pp. : 1-13

Adis International

Access to resources Recommend Favorite

Emerging drugs for complications of end-stage liver disease

By Dowman Joanna K Holt Andrew P Newsome Philip N Adams David H

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 1, 2008-03 ,pp. : 159-174

Informa Healthcare

Access to resources Recommend Favorite

Epidemiology of end-stage renal disease

By Roderick Paul

Clinical Medicine, Vol. 2, Iss. 3, 2002-05 ,pp. : 200-204

Royal College Of Physicians

Access to resources Recommend Favorite

Antidiabetic Agents in Patients with Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: Metabolism and Clinical Practice

Current Drug Metabolism, Vol. 12, Iss. 1, 2011-01 ,pp. : 57-69

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacotherapy for end-stage coronary artery disease

By Sodha Neel R Chu Louis M Boodhwani Munir Sellke Frank W

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 2, 2010-02 ,pp. : 207-213

Informa Healthcare

Access to resources Recommend Favorite